|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zelenetz AD, Abramson JS, Advani RH,
Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ,
Gockerman JP, et al: NCCN Clinical Practice Guidelines in Oncology:
non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 8:288–334.
2010.PubMed/NCBI
|
|
3
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glennie MJ, French RR, Cragg MS and Taylor
RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol
Immunol. 44:3823–3837. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rezvani AR and Maloney DG: Rituximab
resistance. Best Pract Res Clin Haematol. 24:203–216. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vega MI, Martinez-Paniagua M, Jazirehi AR,
Huerta-Yepez S, Umezawa K, Martinez-Maza O and Bonavida B: The
NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise
rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by
various chemotherapeutic drugs. Leuk Lymphoma. 49:1982–1994. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimizu R, Kikuchi J, Wada T, Ozawa K,
Kano Y and Furukawa Y: HDAC inhibitors augment cytotoxic activity
of rituximab by upregulating CD20 expression on lymphoma cells.
Leukemia. 24:1760–1768. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kimby E: Biological therapy doublets:
Pairing rituximab with interferon, lenalidomide, and other
biological agents in patients with follicular lymphoma. Curr
Hematol Malig Rep. 7:221–227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wahlin BE, Sundström C, Holte H, Hagberg
H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B,
Geisler CH, et al: T cells in tumors and blood predict outcome in
follicular lymphoma treated with rituximab. Clin Cancer Res.
17:4136–4144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davis TA, Maloney DG, Grillo-López AJ,
White CA, Williams ME, Weiner GJ, Dowden S and Levy R: Combination
immunotherapy of relapsed or refractory low-grade or follicular
non-Hodgkin's lymphoma with rituximab and inter-feron-alpha-2a.
Clin Cancer Res. 6:2644–2652. 2000.PubMed/NCBI
|
|
11
|
Sacchi S, Federico M, Vitolo U, Boccomini
C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli
F, et al: GISL: Clinical activity and safety of combination
immunotherapy with IFN-alpha 2a and Rituximab in patients with
relapsed low grade non-Hodgkin's lymphoma. Haematologica.
86:951–958. 2001.PubMed/NCBI
|
|
12
|
Kimby E, Jurlander J, Geisler C, Hagberg
H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén
O, et al; Nordic Lymphoma Group. Long-term molecular remissions in
patients with indolent lymphoma treated with rituximab as a single
agent or in combination with interferon alpha-2a: A randomized
phase II study from the Nordic Lymphoma Group. Leuk Lymphoma.
49:102–112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chawla-Sarkar M, Lindner DJ, Liu YF,
Williams BR, Sen GC, Silverman RH and Borden EC: Apoptosis and
interferons: Role of interferon-stimulated genes as mediators of
apoptosis. Apoptosis. 8:237–249. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashida M, Hoshika A, Kanetaka Y, Yanase
N and Mizuguchi J: IFN-alpha sensitizes daudi B lymphoma cells to
anti-IgM induced loss of mitochondrial membrane potential through
activation of c-Jun NH(2)-terminal kinase. J Interferon Cytokine
Res. 26:421–429. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gutterman JU: Cytokine therapeutics:
Lessons from interferon alpha. Proc Natl Acad Sci USA.
91:1198–1205. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spielberger RT, Mick R, Ratain MJ and
Golomb HM: Interferon treatment for hairy cell leukemia. An update
on a cohort of 69 patients treated from 1983 to 1986. Leuk
Lymphoma. 14(Suppl 1): 89–93. 1994.PubMed/NCBI
|
|
17
|
Yanase N, Hayashida M, Kanetaka-Naka Y,
Hoshika A and Mizuguchi J: PKC-δ mediates interferon-α-induced
apoptosis through c-Jun NH(2)-terminal kinase activation. BMC Cell
Biol. 13:7–15. 2012. View Article : Google Scholar
|
|
18
|
Schrama D, Reisfeld RA and Becker JC:
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug
Discov. 5:147–159. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xuan C, Steward KK, Timmerman JM and
Morrison SL: Targeted delivery of interferon-alpha via fusion to
anti-CD20 results in potent antitumor activity against B-cell
lymphoma. Blood. 115:2864–2871. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jazirehi AR, Vega MI and Bonavida B:
Development of rituximab-resistant lymphoma clones with altered
cell signaling and cross-resistance to chemotherapy. Cancer Res.
67:1270–1281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vega MI, Huerta-Yepez S, Martinez-Paniagua
M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn
P, Hanna N, Hariharan K, Jazirehi AR, et al: Rituximab-mediated
cell signaling and chemo/immunosensitization of drug-resistant
B-NHL is independent of its Fc functions. Clin Cancer Res.
15:6582–6594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alas S, Emmanouilides C and Bonavida B:
Inhibition of interleukin 10 by rituximab results in
down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's
lymphoma to apoptosis. Clin Cancer Res. 7:709–723. 2001.PubMed/NCBI
|
|
23
|
Bonavida B: Rituximab-induced inhibition
of antiapoptotic cell survival pathways: Implications in
chemo/immunoresistance, rituximab unresponsiveness, prognostic and
novel therapeutic interventions. Oncogene. 26:3629–3636. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vega MI, Huerta-Yepaz S, Garban H,
Jazirehi A, Emmanouilides C and Bonavida B: Rituximab inhibits p38
MAPK activity in 2F7 B NHL and decreases IL-10 transcription:
Pivotal role of p38 MAPK in drug resistance. Oncogene.
23:3530–3540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Czuczman MS and Gregory SA: The future of
CD20 monoclonal antibody therapy in B-cell malignancies. Leuk
Lymphoma. 51:983–994. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kotenko SV and Pestka S: Jak-Stat signal
transduction pathway through the eyes of cytokine class II receptor
complexes. Oncogene. 19:2557–2565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stark GR, Kerr IM, Williams BR, Silverman
RH and Schreiber RD: How cells respond to interferons. Annu Rev
Biochem. 67:227–264. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salamon D, Adori M, He M, Bönelt P,
Severinson E, Kis LL, Wu L, Ujvari D, Leveau B, Nagy N, et al: Type
I interferons directly down-regulate BCL-6 in primary and
transformed germinal center B cells: Differential regulation in B
cell lines derived from endemic or sporadic Burkitt's lymphoma.
Cytokine. 57:360–371. 2012. View Article : Google Scholar
|
|
29
|
Basso K, Saito M, Sumazin P, Margolin AA,
Wang K, Lim WK, Kitagawa Y, Schneider C, Alvarez MJ, Califano A, et
al: Integrated biochemical and computational approach identifies
BCL6 direct target genes controlling multiple pathways in normal
germinal center B cells. Blood. 115:975–984. 2010. View Article : Google Scholar :
|
|
30
|
Niu H, Ye BH and Dalla-Favera R: Antigen
receptor signaling induces MAP kinase-mediated phosphorylation and
degradation of the BCL-6 transcription factor. Genes Dev.
12:1953–1961. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Phan RT, Saito M, Kitagawa Y, Means AR and
Dalla-Favera R: Genotoxic stress regulates expression of the
proto-oncogene Bcl6 in germinal center B cells. Nat Immunol.
8:1132–1139. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Basso K and Dalla-Favera R: Roles of BCL6
in normal and transformed germinal center B cells. Immunol Rev.
247:172–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cragg MS, Walshe CA, Ivanov AO and Glennie
MJ: The biology of CD20 and its potential as a target for mAb
therapy. Curr Dir Autoimmun. 8:140–174. 2005. View Article : Google Scholar
|
|
34
|
Kuijpers TW, Bende RJ, Baars PA, Grummels
A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ,
Eldering E, et al: CD20 deficiency in humans results in impaired T
cell-independent antibody responses. J Clin Invest. 120:214–222.
2010. View Article : Google Scholar :
|
|
35
|
Xu D, Staedman A and Zhang L: CD20
antibody primes B lymphocytes for type I interferon production.
PLoS One. 8:e679002013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Polyak MJ, Tailor SH and Deans JP:
Identification of a cytoplasmic region of CD20 required for its
redistribution to a detergent-insoluble membrane compartment. J
Immunol. 161:3242–3248. 1998.PubMed/NCBI
|
|
37
|
Jarvis RM, Chamba A, Holder MJ, Challa A,
Smith DC, Hodgkin MN, Lord JM and Gordon J: Dynamic interplay
between the neutral glycosphingolipid CD77/Gb3 and the therapeutic
antibody target CD20 within the lipid bilayer of model B lymphoma
cells. Biochem Biophys Res Commun. 355:944–949. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Holder MJ, Chamba A, Hardie DL, Deans JP
and Gordon J: Improved access to CD20 following B cell receptor
cross-linking at Burkitt's lymphoma cell surfaces. Leuk Res.
28:1197–1202. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Khine AA and Lingwood CA: Functional
significance of globotriaosyl ceramide in interferon-alpha(2)/type
1 interferon receptor-mediated antiviral activity. J Cell Physiol.
182:97–108. 2000. View Article : Google Scholar
|
|
40
|
Maloney MD, Binnington-Boyd B and Lingwood
CA: Globotriaosyl ceramide modulates interferon-alpha-induced
growth inhibition and CD19 expression in Burkitt's lymphoma cells.
Glycoconj J. 16:821–828. 1999. View Article : Google Scholar
|
|
41
|
Rossi EA, Goldenberg DM, Cardillo TM,
Stein R and Chang CH: CD20-targeted tetrameric interferon-alpha, a
novel and potent immunocytokine for the therapy of B-cell
lymphomas. Blood. 114:3864–3871. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rossi EA, Rossi DL, Stein R, Goldenberg DM
and Chang CH: A bispecific antibody-IFNalpha2b immunocytokine
targeting CD20 and HLA-DR is highly toxic to human lymphoma and
multiple myeloma cells. Cancer Res. 70:7600–7609. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brodie C and Blumberg PM: Regulation of
cell apoptosis by protein kinase c delta. Apoptosis. 8:19–27. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jackson DN and Foster DA: The enigmatic
protein kinase Cdelta: Complex roles in cell proliferation and
survival. FASEB J. 18:627–636. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Reyland ME: Protein kinase Cdelta and
apoptosis. Biochem Soc Trans. 35:1001–1004. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saijo K, Mecklenbräuker I, Schmedt C and
Tarakhovsky A: B cell immunity regulated by the protein kinase C
family. Ann NY Acad Sci. 987:125–134. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yanase N, Ohshima K, Ikegami H and
Mizuguchi J: Cytochrome c release, mitochondrial membrane
depolarization, caspase-3 activation, and Bax-alpha cleavage during
IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon
Cytokine Res. 20:1121–1129. 2000. View Article : Google Scholar
|
|
48
|
Yanase N, Hata K, Shimo K, Hayashida M,
Evers BM and Mizuguchi J: Requirement of c-Jun NH2-terminal kinase
activation in interferon-alpha-induced apoptosis through
upregulation of tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res. 310:10–21.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kaur S, Parmar S, Smith J, Katsoulidis E,
Li Y, Sassano A, Majchrzak B, Uddin S, Tallman MS and Fish EN: Role
of protein kinase C-delta (PKC-delta) in the generation of the
effects of IFN-alpha in chronic myelogenous leukemia cells. Exp
Hematol. 33:550–557. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kumar A, Commane M, Flickinger TW, Horvath
CM and Stark GR: Defective TNF-alpha-induced apoptosis in
STAT1-null cells due to low constitutive levels of caspases.
Science. 278:1630–1632. 1997. View Article : Google Scholar : PubMed/NCBI
|
